Amgen and AstraZeneca's DeLLphi-305 Study Hits Primary Endpoint

Pharmaceutical companies Amgen and AstraZeneca have announced that their Phase 3 DeLLphi-305 study has met its primary endpoint. This means that the trial has shown a statistically significant improvement in at least one of the key outcomes measured.

The DeLLphi-305 study is focused on evaluating the efficacy of their treatment for a specific condition, and this result brings them closer to potentially bringing it to market. The exact details of the study's design and results have not been disclosed yet, but this achievement is a significant milestone in the development process.

While this news may be exciting for investors holding shares of Amgen (AMGN) or AstraZeneca (AZN), it's essential to note that backtesting results, which are used to evaluate the performance of investment strategies, should not be taken as indicative of future actual results. The TipRanks Smart Score performance is based on backtested results and has inherent limitations.